Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer’s Drug

FDA
News

FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer’s Drug

https://www.wsj.com/articles/biogen-aduhelm-fda-approval-congressional-investigation-11672333482

byBenzinga Newsdesk

December 29, 2022

1 minute read

https://www.wsj.com/articles/biogen-aduhelm-fda-approval-congressional-investigation-11672333482

What Does MercadoLibre’s Debt Look Like?

By Benzinga Insights

May 18, 12:31 PM

Shares of MercadoLibre Inc. (NASDAQ:MELI) moved higher by 19.45% in the past three months. Before having a look…

MELI

Genmab Announces Q3 Net Sales of $2.5B for DARZALEX (Daratumumab)

By Benzinga Newsdesk

October 17, 6:29 AM

Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under

GMAB

NetApp Q2 Adj. EPS $1.48 Beats $1.33 Estimate, Sales $1.66B Miss $1.68B Estimate

By Michael Horton

November 29, 5:02 PM

NetApp (NASDAQ:NTAP) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.33 by 11.28 percent. This is a 15.62 percent increase over earnings of $1.28 per share from the same

NTAP